Costs don't drive prices. Demand does. I'll be the first to admit that pharmaceutical economics is not simple (lots of externalities, asymmetry of information, etc.), but in the long run costs do matter, and so does price. Best example is Solvaldi, which initially sold for ~$100,000 per treatment. It's much much down (~$65,000) once Merk came online with their hep C competitor. Prices do matter, and while the market is easily distorted, it's not immune to the laws of economics.